Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OI
MCID: ORT004
MIFTS: 68

Orthostatic Intolerance (OI)

Categories: Cardiovascular diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Orthostatic Intolerance

About this section

MalaCards integrated aliases for Orthostatic Intolerance:

Name: Orthostatic Intolerance 57 76 75 37 29 13 6
Mitral Valve Prolapse 12 76 37 29 55 6 43 44 15 63
Neurocirculatory Asthenia 57 12 44 15 73
Mitral Valve Prolapse Syndrome 57 73
Irritable Heart 57 73
Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency 59
Postural Orthostatic Tachycardia Syndrome Due to Net Deficiency 59
Cardiovascular Malfunction Arising from Mental Factors 12
Orthostatic Intolerance Due to Net Deficiency 59
Mitral Valve Prolapse, Familial, X-Linked 73
Myxomatous Mitral Valve Prolapse 12
Systolic Click-Murmur Syndrome 12
Pots Due to Net Deficiency 59
Intolerance, Orthostatic 40
Cardiovascular Neurosis 12
Mitral Leaflet Syndrome 12
Floppy Mitral Valve 12
Da Costa's Syndrome 12
Krishaber's Disease 12
Barlow's Syndrome 12
Soldiers Heart 57
Oi 75

Characteristics:

Orphanet epidemiological data:

59
postural orthostatic tachycardia syndrome due to net deficiency
Inheritance: Autosomal dominant;

HPO:

32
orthostatic intolerance:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Mental diseases Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

OMIM 57 604715
Disease Ontology 12 DOID:11569 DOID:988
ICD9CM 35 306.2
NCIt 50 C50655
Orphanet 59 ORPHA443236
ICD10 via Orphanet 34 I95.1
SNOMED-CT via HPO 69 263681008
Sources

Summaries for Orthostatic Intolerance

About this section
MedlinePlus : 43 Mitral valve prolapse (MVP) occurs when one of your heart's valves doesn't work properly. The flaps of the valve are "floppy" and don't close tightly. Most people who have the condition are born with it. It also tends to run in families. Most of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can cause Palpitations (feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast) Shortness of breath Cough Fatigue, dizziness, or anxiety Migraine headaches Chest discomfort Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications. If you need treatment for MVP, medicines can help relieve symptoms or prevent complications. Very few people will need surgery to repair or replace the mitral valve. MVP puts you at risk for infective endocarditis, a kind of heart infection. To prevent it, doctors used to prescribe antibiotics before dental work or certain surgeries. Now, only people at high risk of endocarditis need the antibiotics. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Orthostatic Intolerance, also known as mitral valve prolapse, is related to postural orthostatic tachycardia syndrome and mitral valve prolapse 1, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Orthostatic Intolerance is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and NFAT and Cardiac Hypertrophy. The drugs Midodrine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are orthostatic tachycardia and cardiovascular system

Disease Ontology : 12 A mitral valve disease where one or both of the cusps of the mitral valve bulge or collapse backward in the left atrium during systole.

UniProtKB/Swiss-Prot : 75 Orthostatic intolerance: Syndrome characterized by lightheadedness, fatigue, altered mentation and syncope. It is associated with postural tachycardia. Plasma norepinephrine concentration is abnormally high.

PubMed Health : 63 About mitral valve prolapse: Mitral (MI-tral) valve prolapse (MVP) is a condition in which the heart's mitral valve doesn't work well. The flaps of the valve are "floppy" and don't close tightly. These flaps normally help seal or open the valve.Much of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can lead to palpitations, shortness of breath, chest pain, and other symptoms. (Palpitations are feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast.)

Wikipedia : 76 Mitral valve prolapse (MVP; a.k.a. floppy mitral valve syndrome, systolic click murmur syndrome or... more...

Description from OMIM: 604715
Sources

Related Diseases for Orthostatic Intolerance

About this section

Diseases in the Orthostatic Intolerance family:

Chronic Orthostatic Intolerance

Diseases related to Orthostatic Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 postural orthostatic tachycardia syndrome 33.7 AGTR1 FBN1 SLC6A2
2 mitral valve prolapse 1 32.5 DCHS1 MMVP1
3 hypermobile ehlers-danlos syndrome 30.8 FBN1 PLOD1
4 arteries, anomalies of 30.4 AGTR1 EDN1 NOS3
5 mitral valve disease 30.4 AGTR1 FBN1 NOS3
6 coronary artery anomaly 30.3 ADRB1 ADRB2 AGTR1 EDN1 NOS3
7 heart disease 30.3 ADRB1 AGTR1 ECE1 EDN1 FLNA NOS3
8 congestive heart failure 30.2 ADRB1 ADRB2 AGTR1 EDN1
9 dilated cardiomyopathy 30.2 ADRA2C ADRB1 ADRB2 AGTR1 EDN1 NOS3
10 myocardial infarction 30.0 ADRA2B ADRB1 ADRB2 AGTR1 EDN1 NOS3
11 aortic coarctation 30.0 ADRB1 ADRB2 AGTR1 EDN1 FBN1 NOS3
12 acute myocardial infarction 29.9 ADRB1 AGTR1 EDN1
13 mitral valve prolapse 2 12.9
14 mitral valve prolapse 3 12.8
15 chronic orthostatic intolerance 12.6
16 mitral valve prolapse, familial, autosomal dominant 12.4
17 hypogonadism-mitral valve prolapse-intellectual disability syndrome 12.4
18 brachydactyly-mesomelia-intellectual disability-heart defects syndrome 12.2
19 brittle bone disorder 12.2
20 osteogenesis imperfecta, type v 12.1
21 osteogenesis imperfecta, type iv 12.0
22 osteogenesis imperfecta, type ii 12.0
23 osteogenesis imperfecta, type viii 11.9
24 osteogenesis imperfecta, type iii 11.9
25 osteogenesis imperfecta, type xiii 11.9
26 osteogenesis imperfecta, type xiv 11.9
27 osteogenesis imperfecta, type xv 11.9
28 osteogenesis imperfecta, type i 11.9
29 osteogenesis imperfecta, type vii 11.8
30 osteogenesis imperfecta, type xi 11.8
31 osteogenesis imperfecta, type x 11.8
32 osteogenesis imperfecta, type vi 11.8
33 cantalamessa baldini ambrosi syndrome 11.7
34 osteogenesis imperfecta, type xii 11.7
35 spastic ataxia, charlevoix-saguenay type 11.6
36 mass syndrome 11.6
37 ehlers-danlos syndrome, classic-like, 2 11.5
38 dentinogenesis imperfecta 11.4
39 arthrogryposis, distal, type 9 11.4
40 polycystic kidney disease 1 with or without polycystic liver disease 11.4
41 ehlers-danlos syndrome, cardiac valvular type 11.4
42 frank-ter haar syndrome 11.4
43 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 1 11.4
44 cardiac valvular dysplasia, x-linked 11.4
45 dental anomalies and short stature 11.4
46 heart valve disease 11.4
47 chromosome 17q11.2 deletion syndrome 11.4
48 dahlberg borer newcomer syndrome 11.4
49 microphthalmia, syndromic 2 11.3
50 col1a1/2-related osteogenesis imperfecta 11.3

Graphical network of the top 20 diseases related to Orthostatic Intolerance:



Diseases related to Orthostatic Intolerance
Sources

Symptoms & Phenotypes for Orthostatic Intolerance

About this section

Clinical features from OMIM:

604715

Human phenotypes related to Orthostatic Intolerance:

32
# Description HPO Frequency HPO Source Accession
1 orthostatic tachycardia 32 HP:0012173

UMLS symptoms related to Orthostatic Intolerance:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Orthostatic Intolerance:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2 homeostasis/metabolism MP:0005376 10.34 ACHE ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
3 behavior/neurological MP:0005386 10.32 ACHE ADRA2A ADRA2B ADRA2C ADRB2 AGTR1
4 growth/size/body region MP:0005378 10.32 ACHE ADRA2B ADRB1 ADRB2 AGTR1 DCHS1
5 mortality/aging MP:0010768 10.31 ACHE ADRA2A ADRA2B ADRA2C ADRB1 AGTR1
6 nervous system MP:0003631 10.17 ACHE ADRA2A ADRA2C ADRB2 AGTR1 DCHS1
7 hematopoietic system MP:0005397 10.16 ACHE ADRA2B ADRB2 AGTR1 ECE1 FBN1
8 adipose tissue MP:0005375 10.13 ACHE ADRB1 ADRB2 AGTR1 FBN1 NOS2
9 muscle MP:0005369 10.07 ACHE ADRA2B ADRB1 ADRB2 ECE1 EDN1
10 no phenotypic analysis MP:0003012 9.8 ACHE ADRB1 ADRB2 DCHS1 FBN1 PLOD1
11 renal/urinary system MP:0005367 9.76 ADRA2B AGTR1 DCHS1 EDN1 FBN1 NOS2
12 respiratory system MP:0005388 9.5 ACHE ADRA2B DCHS1 FBN1 FLNA NOS2
13 skeleton MP:0005390 9.32 ADRB1 ADRB2 DCHS1 ECE1 EDN1 FBN1
Sources

Drugs & Therapeutics for Orthostatic Intolerance

About this section

PubMedHealth treatment related to Orthostatic Intolerance: 63

Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications.Even people who do have symptoms may not need treatment. The presence of symptoms doesn't always mean that the backflow of blood through the valve is significant.People who have MVP and troublesome mitral valve backflow usually need treatment. MVP is treated with medicines, surgery, or both.The goals of treating MVP include:Preventing infective endocarditis (IE), arrhythmias, and other complicationsRelieving symptomsCorrecting the underlying mitral valve problem, if necessary

Drugs for Orthostatic Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
2
Norepinephrine Approved Phase 4,Phase 2,Phase 1 51-41-2 439260
3
Metoprolol Approved, Investigational Phase 4,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
4
Propranolol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 525-66-6 4946
5
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23651-95-8 443940
9
Bisoprolol Approved Phase 4 66722-44-9 2405
10
Fludrocortisone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 127-31-1 31378
11 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Atomoxetine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
25 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
26 Sympatholytics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Vasodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 Narcotics Phase 4
29 Antipyretics Phase 4
30 Cola Phase 4
31 Anesthetics, Local Phase 4,Phase 1,Not Applicable
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
33 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
34 Anesthetics Phase 4,Phase 1,Not Applicable
35 Analgesics, Opioid Phase 4
36 Analgesics Phase 4,Phase 1,Phase 2
37 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Cholinergic Agents Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable
39 Pyridostigmine Bromide Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 101-26-8
40 Bromides Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Anticonvulsants Phase 4,Phase 1,Phase 2
42 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 50-24-8 5755
45
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 83-43-2 6741
46
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Not Applicable 302-25-0
47
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Not Applicable 2921-57-5
48
Carbidopa Approved Phase 2, Phase 3,Phase 3,Phase 1 28860-95-9 34359 38101
49
Dopamine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
50
Metoclopramide Approved, Investigational Phase 3,Phase 1 364-62-5 4168

Interventional clinical trials:

(show top 50) (show all 210)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Unknown status NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
3 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
4 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
5 TQL-block for Laparoscopic Hemicolectomy Recruiting NCT03570541 Phase 4 Ropivacaine;Acetaminophen;Morphine;Saline
6 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
7 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
8 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
9 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
10 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
11 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
12 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
13 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
14 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
15 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
16 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Recruiting NCT03229174 Phase 4 Droxidopa;Placebo
17 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Completed NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
18 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
19 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
20 Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Completed NCT02445898 Phase 2, Phase 3 Methylprednisolone;Isotonic Sodium Chloride
21 Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty Completed NCT01707953 Phase 3 Midodrine;Placebo
22 A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
23 Peripheral Dopamine in Postural Tachycardia Syndrome Active, not recruiting NCT00685919 Phase 2, Phase 3 Carbidopa;Placebo
24 Treatment of Orthostatic Hypotension Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
25 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
26 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
27 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
28 APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
29 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure Recruiting NCT03750552 Phase 3 TD-9855;Placebo
30 Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients Terminated NCT01612078 Phase 3 Droxidopa;Placebo
31 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Recruiting NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
32 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Recruiting NCT03182725 Phase 3 Ivabradine;Placebo
33 Treatment of Post-SCI Hypotension Recruiting NCT02919917 Phase 2, Phase 3 Midodrine Hydrochloride;Midodrine Hydrochloride
34 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
35 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
36 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
37 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
38 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
39 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope Unknown status NCT02874937 Phase 2 Atomoxetine;Matching Placebo
40 The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome Unknown status NCT01761825 Phase 2 ivabradine
41 Cardiovascular Effects of Selective I(f)-Channel Blockade Unknown status NCT00865917 Phase 2 beta-blocker (Metoprolol);I(f)-blocker (ivabradine);Placebo
42 Fipamezole in Neurogenic Orthostatic Hypotension Unknown status NCT00758849 Phase 2 Placebo;Fipamezole
43 Treatment of Orthostatic Intolerance Active, not recruiting NCT00262470 Phase 1, Phase 2 Acetazolamide;Atomoxetine;Clonidine;Entacapone;Entacapone & Propranolol;Atomoxetine & Propranolol;Indomethacin;Mecamylamine;Isosorbide Dinitrate;Midodrine;Modafinil;Octreotide;Propranolol;Modafinil & Propranolol;Sertraline;memantine
44 Sex Hormones and Orthostatic Tolerance Completed NCT01153581 Phase 2 Ganirelix acetate;17β-Oestradiol;Progesterone
45 Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist Terminated NCT03070730 Phase 1, Phase 2 Droxidopa;Atenolol;Placebos
46 Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) Recruiting NCT02558972 Phase 2 Northera (Droxidopa);Placebo;Northera (Droxidopa);Placebo
47 TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Active, not recruiting NCT02705755 Phase 2 TD-9855;Placebo
48 Non-Pharmacologic Therapy for Neurocardiogenic Syncope Completed NCT00096902 Phase 2
49 Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Recruiting NCT03613129 Phase 1, Phase 2 CT38
50 Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance Completed NCT00093860 Phase 2 Propranolol

Search NIH Clinical Center for Orthostatic Intolerance

Cochrane evidence based reviews: neurocirculatory asthenia

Sources

Genetic Tests for Orthostatic Intolerance

About this section

Genetic tests related to Orthostatic Intolerance:

# Genetic test Affiliating Genes
1 Orthostatic Intolerance 29 SLC6A2
2 Mitral Valve Prolapse 29
Sources

Anatomical Context for Orthostatic Intolerance

About this section

MalaCards organs/tissues related to Orthostatic Intolerance:

41
Heart, Testes, Lung, Brain, Spinal Cord, Liver, Bone
Sources

Publications for Orthostatic Intolerance

About this section

Articles related to Orthostatic Intolerance:

(show top 50) (show all 1426)
# Title Authors Year
1
Prevalence and clinical phenotype of concomitant long QT syndrome and arrhythmogenic bileaflet mitral valve prolapse. ( 30219255 )
2019
2
Unusual combination of mitral valve prolapse, bicuspid aortic valve, and ventricular septal defect restricted by the tricuspid septal leaflet. ( 29339711 )
2018
3
Intravenous saline administration in patients with severe acquired brain injury and orthostatic intolerance for tilt-table mobilization. ( 29190150 )
2018
4
Weighting of orthostatic intolerance time measurements with standing difficulty score stratifies ME/CFS symptom severity and analyte detection. ( 29650052 )
2018
5
Orthostatic tachycardia with different onset time in patients with orthostatic intolerance. ( 29801880 )
2018
6
Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. ( 29969498 )
2018
7
Orthostatic intolerance and postural tachycardia syndrome: new insights into pathophysiology and treatment. ( 29696346 )
2018
8
The etiologic relation between disequilibrium and orthostatic intolerance in patients with myalgic encephalomyelitis (chronic fatigue syndrome). ( 29588088 )
2018
9
Emotional orienting during interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological symptomatology in the postural tachycardia syndrome and vasovagal syncope. ( 29519640 )
2018
10
Pediatric Disorders of Orthostatic Intolerance. ( 29222399 )
2018
11
Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. ( 29519641 )
2018
12
Changes in the augmentation index and postoperative orthostatic intolerance in orthopedic surgery: a prospective cohort study. ( 29790120 )
2018
13
Mitral valve prolapse and aortic root dilation in adults with hypermobile Ehlers-Danlos syndrome and related disorders. ( 30063091 )
2018
14
Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. ( 29903346 )
2018
15
Prefrontal hemodynamic changes measured using near-infrared spectroscopy during the Valsalva maneuver in patients with orthostatic intolerance. ( 29392157 )
2018
16
Orthostatic intolerance in enhanced recovery laparoscopic colorectal resection. ( 30094811 )
2018
17
Chronic nausea and orthostatic intolerance: Diagnostic utility of orthostatic challenge duration, Nausea Profile Questionnaire, and neurohumoral measures. ( 30101470 )
2018
18
Assessment of cerebral autoregulation using continuous-wave near-infrared spectroscopy during squat-stand maneuvers in subjects with symptoms of orthostatic intolerance. ( 30185974 )
2018
19
Hypocapnic cerebral hypoperfusion: A biomarker of orthostatic intolerance. ( 30256820 )
2018
20
Orthostatic Intolerance and Coagulation Abnormalities: An Update. ( 30315398 )
2018
21
Cardiovascular variability in young male and female subjects in health and orthostatic intolerance. ( 30441020 )
2018
22
Utility of Diagnostic Studies for Upper Gastrointestinal Symptoms in Children with Orthostatic Intolerance. ( 30529135 )
2018
23
Orthostatic intolerance following hip arthroplasty: Incidence, risk factors and effect on length of stay: a prospective cohort study. ( 30540643 )
2018
24
The Prevalence of Mitral Valve Prolapse in Panic Disorder: A Meta-Analysis. ( 30448200 )
2018
25
A Case of Single Atrium, Mitral Valve Prolapse Spontaneously - Closed Inlet VSD with Polydactyly. ( 30487512 )
2018
26
Association between mitral valve prolapse and sudden sensorineural hearing loss: A case-control population-based study. ( 30286192 )
2018
27
An unusual case of double-chambered left ventricle : A case of double-chambered left ventricle communicated with right ventricle through a ventricular septal defect presented during only in diastole and a concomitant mitral valve prolapse. ( 30097833 )
2018
28
Coexistent bicuspid aortic valve and mitral valve prolapse: epidemiology, phenotypic spectrum, and clinical implications. ( 30445616 )
2018
29
Correction to: Hiatal hernia, mitral valve prolapse and defecatory disorders: An underlying rectal prolapse? ( 30324409 )
2018
30
Corneal Sublayers Thickness in Patients With Mitral Valve Prolapse. ( 27541972 )
2018
31
Imaging characteristics of papillary muscle site of origin of ventricular arrhythmias in patients with mitral valve prolapse. ( 29059484 )
2018
32
Aortic elasticity and carotid intima-media thickness in children with mitral valve prolapse. ( 29110750 )
2018
33
Deleterious variants in DCHS1 are prevalent in sporadic cases of mitral valve prolapse. ( 29224215 )
2018
34
Genetics of syndromic and non-syndromic mitral valve prolapse. ( 29352010 )
2018
35
Assesment of Rhythm Disorders in Classical and Nonclassical Mitral Valve Prolapse. ( 29416210 )
2018
36
Transthoracic echocardiography in patients undergoing mitral valve repair: comparison of new transthoracic 3D techniques to 2D transoesophageal echocardiography in the localization of mitral valve prolapse. ( 29484557 )
2018
37
Papillary muscle ventricular arrhythmias among patients with mitral valve prolapse. ( 29485223 )
2018
38
Genomic analysis in patients with myxomatous mitral valve prolapse: current state of knowledge. ( 29486707 )
2018
39
Grading of mitral regurgitation in mitral valve prolapse using the average pixel intensity method. ( 29544951 )
2018
40
Grading of mitral valve prolapse with late systolic regurgitation using automated intensity analysis of continuous wave Doppler. ( 29544954 )
2018
41
To what extent can 3D model replicate dimensions of individual mitral valve prolapse? ( 29556869 )
2018
42
Mechanistic insights of the left ventricle structure and fibrosis in the arrhythmogenic mitral valve prolapse. ( 29644231 )
2018
43
Mitral valve prolapse causes arrhythmias from the papillary muscles: A stretch of the truth or reality? ( 29719059 )
2018
44
Catheter ablation of papillary muscle arrhythmias: Implications of mitral valve prolapse and systolic dysfunction. ( 29732567 )
2018
45
Prevalence and Clinical Outcome of Athletes With Mitral Valve Prolapse. ( 29735594 )
2018
46
Implanting neochordae for the repair of mitral valve prolapse using a prosthetic ring with chordal sizing system: a modified technique for myxomatous leaflets. ( 29782080 )
2018
47
Recurrent premature ventricular contraction-induced ventricular fibrillation and resuscitated sudden death in a 26-year-old pregnant woman with bileaflet mitral valve prolapse. ( 29876289 )
2018
48
Mitral valve repair results in suppression of ventricular arrhythmias and normalization of repolarization abnormalities in mitral valve prolapse. ( 29915716 )
2018
49
Relation of mitral valve morphology to surgical repair results in patients with mitral valve prolapse: A three-dimensional transesophageal echocardiography study. ( 29920772 )
2018
50
Cardiac magnetic resonance in patients with mitral valve prolapse: Focus on late gadolinium enhancement and T1 mapping. ( 30088066 )
2018
Sources

Variations for Orthostatic Intolerance

About this section

UniProtKB/Swiss-Prot genetic disease variations for Orthostatic Intolerance:

75
# Symbol AA change Variation ID SNP ID
1 SLC6A2 p.Ala457Pro VAR_010022 rs121918126

ClinVar genetic disease variations for Orthostatic Intolerance:

6 (show top 50) (show all 141)
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC6A2 NM_001172504.1(SLC6A2): c.1369G> C (p.Ala457Pro) single nucleotide variant Pathogenic rs121918126 GRCh37 Chromosome 16, 55731917: 55731917
2 SLC6A2 NM_001172504.1(SLC6A2): c.1369G> C (p.Ala457Pro) single nucleotide variant Pathogenic rs121918126 GRCh38 Chromosome 16, 55698005: 55698005
3 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh37 Chromosome 11, 47433573: 47433573
4 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh38 Chromosome 11, 47412022: 47412022
5 BMPR2 NM_001204.6(BMPR2): c.2948G> A (p.Arg983Gln) single nucleotide variant Likely benign rs148099152 GRCh38 Chromosome 2, 202559777: 202559777
6 BMPR2 NM_001204.6(BMPR2): c.2948G> A (p.Arg983Gln) single nucleotide variant Likely benign rs148099152 GRCh37 Chromosome 2, 203424500: 203424500
7 SLC6A2 NM_001043.3(SLC6A2): c.-182C> T single nucleotide variant Likely benign rs2242446 GRCh38 Chromosome 16, 55656513: 55656513
8 SLC6A2 NM_001043.3(SLC6A2): c.-182C> T single nucleotide variant Likely benign rs2242446 GRCh37 Chromosome 16, 55690425: 55690425
9 SLC6A2 NM_001043.3(SLC6A2): c.21C> A (p.Asn7Lys) single nucleotide variant Uncertain significance rs11568323 GRCh38 Chromosome 16, 55656715: 55656715
10 SLC6A2 NM_001043.3(SLC6A2): c.21C> A (p.Asn7Lys) single nucleotide variant Uncertain significance rs11568323 GRCh37 Chromosome 16, 55690627: 55690627
11 SLC6A2 NM_001043.3(SLC6A2): c.48G> C (p.Gly16=) single nucleotide variant Uncertain significance rs551459843 GRCh38 Chromosome 16, 55656742: 55656742
12 SLC6A2 NM_001043.3(SLC6A2): c.48G> C (p.Gly16=) single nucleotide variant Uncertain significance rs551459843 GRCh37 Chromosome 16, 55690654: 55690654
13 SLC6A2 NM_001043.3(SLC6A2): c.52G> C (p.Asp18His) single nucleotide variant Uncertain significance rs886052131 GRCh38 Chromosome 16, 55656746: 55656746
14 SLC6A2 NM_001043.3(SLC6A2): c.52G> C (p.Asp18His) single nucleotide variant Uncertain significance rs886052131 GRCh37 Chromosome 16, 55690658: 55690658
15 SLC6A2 NM_001043.3(SLC6A2): c.275-15C> T single nucleotide variant Uncertain significance rs886052132 GRCh38 Chromosome 16, 55669550: 55669550
16 SLC6A2 NM_001043.3(SLC6A2): c.275-15C> T single nucleotide variant Uncertain significance rs886052132 GRCh37 Chromosome 16, 55703462: 55703462
17 SLC6A2 NM_001043.3(SLC6A2): c.866A> G (p.Asn289Ser) single nucleotide variant Uncertain significance rs77951841 GRCh37 Chromosome 16, 55725912: 55725912
18 SLC6A2 NM_001043.3(SLC6A2): c.866A> G (p.Asn289Ser) single nucleotide variant Uncertain significance rs77951841 GRCh38 Chromosome 16, 55692000: 55692000
19 SLC6A2 NM_001043.3(SLC6A2): c.918+11A> G single nucleotide variant Likely benign rs5564 GRCh37 Chromosome 16, 55725975: 55725975
20 SLC6A2 NM_001043.3(SLC6A2): c.918+11A> G single nucleotide variant Likely benign rs5564 GRCh38 Chromosome 16, 55692063: 55692063
21 SLC6A2 NM_001043.3(SLC6A2): c.1401C> T (p.Tyr467=) single nucleotide variant Uncertain significance rs138435822 GRCh37 Chromosome 16, 55732392: 55732392
22 SLC6A2 NM_001043.3(SLC6A2): c.1401C> T (p.Tyr467=) single nucleotide variant Uncertain significance rs138435822 GRCh38 Chromosome 16, 55698480: 55698480
23 SLC6A2 NM_001043.3(SLC6A2): c.1465G> A (p.Ala489Thr) single nucleotide variant Uncertain significance rs762006683 GRCh37 Chromosome 16, 55732456: 55732456
24 SLC6A2 NM_001043.3(SLC6A2): c.1465G> A (p.Ala489Thr) single nucleotide variant Uncertain significance rs762006683 GRCh38 Chromosome 16, 55698544: 55698544
25 SLC6A2 NM_001043.3(SLC6A2): c.*371G> A single nucleotide variant Likely benign rs115138076 GRCh38 Chromosome 16, 55702717: 55702717
26 SLC6A2 NM_001043.3(SLC6A2): c.*371G> A single nucleotide variant Likely benign rs115138076 GRCh37 Chromosome 16, 55736629: 55736629
27 SLC6A2 NM_001043.3(SLC6A2): c.*396_*397dupCC duplication Uncertain significance rs886052135 GRCh38 Chromosome 16, 55702742: 55702743
28 SLC6A2 NM_001043.3(SLC6A2): c.*396_*397dupCC duplication Uncertain significance rs886052135 GRCh37 Chromosome 16, 55736654: 55736655
29 SLC6A2 NM_001043.3(SLC6A2): c.*414_*415insC insertion Uncertain significance rs886052137 GRCh38 Chromosome 16, 55702760: 55702761
30 SLC6A2 NM_001043.3(SLC6A2): c.*414_*415insC insertion Uncertain significance rs886052137 GRCh37 Chromosome 16, 55736672: 55736673
31 SLC6A2 NM_001043.3(SLC6A2): c.*416delC deletion Uncertain significance rs113163898 GRCh38 Chromosome 16, 55702762: 55702762
32 SLC6A2 NM_001043.3(SLC6A2): c.*416delC deletion Uncertain significance rs113163898 GRCh37 Chromosome 16, 55736674: 55736674
33 SLC6A2 NM_001043.3(SLC6A2): c.*417T> A single nucleotide variant Likely benign rs40615 GRCh38 Chromosome 16, 55702763: 55702763
34 SLC6A2 NM_001043.3(SLC6A2): c.*417T> A single nucleotide variant Likely benign rs40615 GRCh37 Chromosome 16, 55736675: 55736675
35 SLC6A2 NM_001043.3(SLC6A2): c.*606T> C single nucleotide variant Likely benign rs111663130 GRCh38 Chromosome 16, 55702952: 55702952
36 SLC6A2 NM_001043.3(SLC6A2): c.*606T> C single nucleotide variant Likely benign rs111663130 GRCh37 Chromosome 16, 55736864: 55736864
37 SLC6A2 NM_001043.3(SLC6A2): c.*919_*921delACC deletion Uncertain significance rs886052140 GRCh38 Chromosome 16, 55703265: 55703267
38 SLC6A2 NM_001043.3(SLC6A2): c.*919_*921delACC deletion Uncertain significance rs886052140 GRCh37 Chromosome 16, 55737177: 55737179
39 SLC6A2 NM_001043.3(SLC6A2): c.*1017G> A single nucleotide variant Uncertain significance rs886052141 GRCh38 Chromosome 16, 55703363: 55703363
40 SLC6A2 NM_001043.3(SLC6A2): c.*1017G> A single nucleotide variant Uncertain significance rs886052141 GRCh37 Chromosome 16, 55737275: 55737275
41 SLC6A2 NM_001043.3(SLC6A2): c.*1175A> G single nucleotide variant Uncertain significance rs886052142 GRCh38 Chromosome 16, 55703521: 55703521
42 SLC6A2 NM_001043.3(SLC6A2): c.*1175A> G single nucleotide variant Uncertain significance rs886052142 GRCh37 Chromosome 16, 55737433: 55737433
43 SLC6A2 NM_001043.3(SLC6A2): c.407-12G> A single nucleotide variant Likely benign rs11568343 GRCh38 Chromosome 16, 55671926: 55671926
44 SLC6A2 NM_001043.3(SLC6A2): c.407-12G> A single nucleotide variant Likely benign rs11568343 GRCh37 Chromosome 16, 55705838: 55705838
45 SLC6A2 NM_001043.3(SLC6A2): c.848C> G (p.Thr283Arg) single nucleotide variant Likely benign rs45564432 GRCh37 Chromosome 16, 55725894: 55725894
46 SLC6A2 NM_001043.3(SLC6A2): c.848C> G (p.Thr283Arg) single nucleotide variant Likely benign rs45564432 GRCh38 Chromosome 16, 55691982: 55691982
47 SLC6A2 NM_001043.3(SLC6A2): c.1389+9G> A single nucleotide variant Likely benign rs998424 GRCh37 Chromosome 16, 55731946: 55731946
48 SLC6A2 NM_001043.3(SLC6A2): c.1389+9G> A single nucleotide variant Likely benign rs998424 GRCh38 Chromosome 16, 55698034: 55698034
49 SLC6A2 NM_001043.3(SLC6A2): c.1489+9G> A single nucleotide variant Uncertain significance rs760893401 GRCh38 Chromosome 16, 55698577: 55698577
50 SLC6A2 NM_001043.3(SLC6A2): c.1489+9G> A single nucleotide variant Uncertain significance rs760893401 GRCh37 Chromosome 16, 55732489: 55732489
Sources

Expression for Orthostatic Intolerance

About this section
Search GEO for disease gene expression data for Orthostatic Intolerance.
Sources

Pathways for Orthostatic Intolerance

About this section

Pathways related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 13.4 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.7 ADRA2A ADRA2B ADRB1 ADRB2 EDN1
3
Vascular smooth muscle contraction 37
Show member pathways
 12.44 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
4
ADP signalling through P2Y purinoceptor 12 66
Show member pathways
 12.35 ADRA2A ADRA2B ADRA2C ADRB2 POMC
5
Calcium signaling pathway 37
Show member pathways
 12.07 ADRB1 ADRB2 AGTR1 NOS2 NOS3
6
AMPK Enzyme Complex Pathway 64
Show member pathways
 12 ADRA2A ADRA2B ADRA2C NOS2 NOS3
7
Monoamine GPCRs 1
Show member pathways
 11.78 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
8
HIF-1 signaling pathway 37
11.77 EDN1 NOS2 NOS3
9
AGE-RAGE signaling pathway in diabetic complications 37
11.76 AGTR1 EDN1 NOS3
10
Integrin alphaIIb beta3 signaling 66
Show member pathways
 11.74 ADRA2A ADRA2B ADRA2C
11
Corticotropin-releasing hormone signaling pathway 1
11.7 ECE1 NOS3 POMC
12
Renin secretion 37
11.5 ADRB1 ADRB2 AGTR1
13
Antiarrhythmic Pathway, Pharmacodynamics 61
11.42 ADRA2A ADRB1 ADRB2
14
G-protein signaling_Cross-talk between Ras-family GTPases 22
11.22 ADRA2A ADRA2B ADRB1 ADRB2
15
Melatonin metabolism and effects 1
11.02 ACHE ADRB1 ECE1 EDN1
16
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.01 AGTR1 FBN1 FLNA
17
Endothelin Pathways 1
10.79 ADRB1 ECE1 EDN1 NOS3
18
NO-dependent CFTR activation (normal and CF) 22
10.66 NOS2 NOS3
19
Sympathetic Nerve Pathway (Neuroeffector Junction) 61
10.46 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 SLC6A2
20
Effects of Nitric Oxide 1
10.43 NOS2 NOS3
Sources

GO Terms for Orthostatic Intolerance

About this section

Cellular components related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2 plasma membrane GO:0005886 9.47 ACHE ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
3 Weibel-Palade body GO:0033093 8.96 ECE1 EDN1

Biological processes related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.89 ADRA2B ADRA2C EDN1 POMC
2 positive regulation of MAPK cascade GO:0043410 9.85 ADRA2A ADRA2B ADRA2C ADRB2
3 kidney development GO:0001822 9.82 AGTR1 DCHS1 FBN1
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.81 ADRA2A ADRB1 ADRB2
5 platelet activation GO:0030168 9.81 ADRA2A ADRA2B ADRA2C FLNA
6 positive regulation of cold-induced thermogenesis GO:0120162 9.8 ACHE ADRB1 ADRB2
7 regulation of insulin secretion GO:0050796 9.76 ADRA2A ADRA2C NOS2
8 regulation of blood pressure GO:0008217 9.74 EDN1 NOS3 POMC
9 activation of protein kinase B activity GO:0032148 9.7 ADRA2A ADRA2B ADRA2C
10 regulation of sodium ion transport GO:0002028 9.65 ADRB2 NOS3
11 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.65 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
12 nitric oxide mediated signal transduction GO:0007263 9.64 NOS2 NOS3
13 regulation of blood vessel size GO:0050880 9.64 EDN1 NOS3
14 negative regulation of norepinephrine secretion GO:0010700 9.63 ADRA2A ADRA2B ADRA2C
15 negative regulation of calcium ion transport GO:0051926 9.62 ADRA2A NOS3
16 regulation of blood vessel diameter GO:0097746 9.62 ADRB2 AGTR1
17 regulation of smooth muscle contraction GO:0006940 9.62 ADRA2A ADRA2B ADRA2C ADRB2
18 nitric oxide biosynthetic process GO:0006809 9.61 NOS2 NOS3
19 negative regulation of multicellular organism growth GO:0040015 9.61 ADRB1 ADRB2
20 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.61 ECE1 EDN1 NOS3
21 positive regulation of guanylate cyclase activity GO:0031284 9.6 NOS2 NOS3
22 diet induced thermogenesis GO:0002024 9.58 ADRB1 ADRB2
23 negative regulation of epinephrine secretion GO:0032811 9.58 ADRA2A ADRA2B ADRA2C
24 arginine catabolic process GO:0006527 9.56 NOS2 NOS3
25 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.54 ADRB1 ADRB2
26 receptor transactivation GO:0035624 9.54 ADRA2A ADRA2B ADRA2C
27 heat generation GO:0031649 9.48 ADRB1 ADRB2
28 adrenergic receptor signaling pathway GO:0071875 9.46 ADRA2A ADRA2B ADRA2C ADRB2
29 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.35 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
30 regulation of vasoconstriction GO:0019229 9.1 ADRA2A ADRA2B ADRA2C AGTR1 ECE1 EDN1
31 G protein-coupled receptor signaling pathway GO:0007186 10.1 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1

Molecular functions related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.92 ACHE ADRA2A ADRA2C ADRB2 ECE1 FLNA
2 hormone activity GO:0005179 9.69 EDN1 FBN1 POMC
3 FMN binding GO:0010181 9.49 NOS2 NOS3
4 arginine binding GO:0034618 9.48 NOS2 NOS3
5 NADPH-hemoprotein reductase activity GO:0003958 9.46 NOS2 NOS3
6 alpha-2A adrenergic receptor binding GO:0031694 9.43 ADRA2C ADRB1
7 norepinephrine binding GO:0051380 9.43 ADRA2A ADRB1 ADRB2
8 tetrahydrobiopterin binding GO:0034617 9.4 NOS2 NOS3
9 nitric-oxide synthase activity GO:0004517 9.37 NOS2 NOS3
10 adrenergic receptor activity GO:0004935 9.35 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
11 alpha2-adrenergic receptor activity GO:0004938 9.33 ADRA2A ADRA2B ADRA2C
12 epinephrine binding GO:0051379 9.02 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
Sources

Sources for Orthostatic Intolerance

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....